Reduced type II interleukin-4 receptor signalling drives initiation, but not progression, of colorectal carcinogenesis: Evidence from transgenic mouse models and human case-control epidemiological observations

Carcinogenesis

Volumn 34, Issue 10, 2013, Pages 2341-2349

  Ingram, Nicola ^a   Northwood, Emma L ^a   Perry, Sarah L ^a   Marston, Gemma ^a   Snowden, Helen ^a   Taylor, John C ^a   Scott, Nigel ^a   Timothy, Bishop D ^a   Louise, Coletta P ^a   Hull, Mark A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; BETA CATENIN; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6;

ADULT; AGED; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER MORTALITY; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE; GENETIC SUSCEPTIBILITY; HUMAN; INTERLEUKIN 4 RECEPTOR ALPHA GENE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPLEEN CELL; TUMOR GROWTH; TUMOR VOLUME;

AGED; ANIMALS; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN-4, TYPE II; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84885140762     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt222     Document Type: Article

References (43)

1. Chan, A.T. et al. (2010) Primary prevention of colorectal cancer. Gastroenterology, 138, 2029-2043.e10.
2. Lasisi, F. et al. (2011) Improving protection against proximal colon cancer by colonoscopy. Expert Rev. Gastroenterol. Hepatol., 5, 745-754.
3. Zauber, A.G. et al. (2012) Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N. Engl. J. Med., 366, 687-696.
4. Wu, X. et al. (2011) Chemoprevention-history and general principles. Best Pract. Res. Clin. Gastroenterol., 25, 445-459.
5. Terzic, J. et al. (2010) Inflammation and colon cancer. Gastroenterology, 138, 2101-2114.e5.
6. Ben-Nariah, Y. et al. (2011) Inflammation meets cancer, with NF?nflammation meets ca Nature Immunol., 12, 715-723.
7. Nelms, K. et al. (1998) Interleukin-4 receptor signalling mechanisms and their biological significance. Adv. Exp. Med. Biol., 452, 37-43.
8. Terabe, M. et al. (2004) Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol. Immunother., 53, 79-85.
9. Fichtner-Feigl, S. et al. (2006) IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med., 12, 99-106.
10. Kawakami, K. et al. (2001) Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit. Rev. Immunol., 21, 299-310.
11. Koller, F.L. et al. (2010) Epithelial interleukin-4 receptor expression promotes colon tumor growth. Carcinogenesis, 31, 1010-1017.
12. Terabe, M. et al. (2000) NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol., 1, 515-520.
13. Olver, S. et al. (2007) The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth? Tissue Antigens, 69, 293-298.
14. Li, Z. et al. (2008) Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res., 68, 8687-8694.
15. Todaro, M. et al. (2008) Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ., 15, 762-772.
16. Gallina, G. et al. (2006) Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest., 116, 2777-2790.
17. Ko, C.W. et al. (2008) Lack of interleukin-4 receptor alpha chain-dependent signalling promotes azoxymethane-induced colorectal aberrant crypt focus formation in Balb/c mice. J. Pathol., 214, 603-609.
18. Osawa, E. et al. (2006) Predominant T helper type 2-inflammatory responses promote murine colon cancers. Int. J. Cancer, 118, 2232-2236.
19. Hershey, G.K. et al. (1997) The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N. Engl. J. Med., 337, 1720-1725.
20. Wang, H.Y. et al. (1999) Cutting edge: effects of an allergy-associated mutation in the human IL-4R alpha (Q576R) on human IL-4-induced signal transduction. J. Immunol., 162, 4385-4389.
21. Tachdjian, R. et al. (2009) Pathogenicity of a disease-associated human IL-4 receptor allele in experimental asthma. J. Exp. Med., 206, 2191-2204.
22. Kruse, S. et al. (1999) The polymorphisms S503P and Q576R in the interleukin- 4 receptor alpha gene are associated with atopy and influence the signal transduction. Immunology, 96, 365-371.
23. McKenzie, G.J. et al. (1998) A distinct role for interleukin-13 in Th2-cellmediated immune responses. Curr. Biol., 8, 339-342.
24. Barrett, J.H. et al. (2003) Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer. Carcinogenesis, 24, 275-282.
25. Lightfoot, T.J. et al. (2008) Methylene tetrahydrofolate reductase genotype modifies the chemopreventive effect of folate in colorectal adenoma, but not colorectal cancer. Cancer Epidemiol. Biomarkers Prev., 17, 2421-2430.
26. Lampropoulos, P. et al. (2012) TGF-beta signalling in colon carcinogenesis. Cancer Lett., 314, 1-7.
27. Tenbaum, S.P. et al. (2012) β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat. Med., 18, 892-901.
28. Burmeister Getz, E. et al. (2009) Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J. Clin. Pharmacol., 49, 1025-1036.
29. Kopf, M. et al. (2010) Averting inflammation by targeting the cytokine environment. Nat. Rev. Drug Discov., 9, 703-718.
30. Shpitz, B. et al. (1996) Natural history of aberrant crypt foci. A surgical approach. Dis. Colon Rectum, 39, 763-767.
31. Hosono, K. et al. (2010) Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol. Carcinog., 49, 662-671.
32. Schmalhofer, O. et al. (2009) E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev., 28, 151-166.
33. Notani, D. et al. (2010) Global regulator SATB1 recruits beta-catenin and regulates T(H)2 differentiation in Wnt-dependent manner. PLoS Biol., 8, e1000296.
34. Kaklamanis, L. et al. (1992) Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer. Br. J. Cancer, 66, 712-716.
35. Todaro, M. et al. (2007) Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell, 1, 389-402.
36. Formentini, A. et al. (2012) Expression of interleukin-4 and interleukin- 13 and their receptors in colorectal cancer. Int. J. Colorectal Dis., 27, 1369-1376.
37. Sun, H.L. et al. (2012) Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J. Gastroenterol., 18, 3303-3309.
38. Zhang, B. et al. (2013) Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS ONE, 8:e57114.
39. Lee, Y.S. et al. (2010) Association between interleukin-4R and TGF-β1 gene polymorphisms and the risk of colorectal cancer in a Korean population. Colorectal Dis., 12, 1208-1212.
40. Landi, S. et al. (2007) Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk. Eur. J. Cancer, 43, 762-768.
41. Jimenez-Sousa, M.A. et al. (2012) Genetic polymorphisms located in genes related to immune and inflammatory processes are associated with endstage renal disease: a preliminary study. BMC Med. Genet., 13, 58.
42. Li, S. et al. (2012) Polymorphisms of TREH, IL4R and CCDC26 genes associated with risk of glioma. Cancer Epidemiol., 36, 283-287.
43. Esposito, D.L. et al. (2012) The insulin receptor substrate 1 (IRS1) in intestinal epithelial differentiation and in colorectal cancer. PLoS One, 7, e36190.